LONG‐TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS‐2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Authors: Caimi, P. F, Ai, W. Z, Alderuccio, J. P., Ardeshna, K. M, Hamadani, M., Hess, B., Kahl, B. S, Radford, J., Solh, M., Stathis, A., Zinzani, P. L., Wang, Y., Qin, Y., Wang, L., Xu, C., Carlo‐Stella, C.

Source: Hematological oncology. 41:209-212

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185003146.0x000001&indx=1&recIds=ETOCvdc_100185003146.0x000001

Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6‐year follow‐up of CHRONOS‐1

Authors: Dreyling, M., Santoro, A., Mollica, L., Leppä, S., Follows, G. A., Lenz, G., Kim, W. S., Nagler, A., Panayiotidis, P., Demeter, J., Özcan, M., Kosinova, M., Provencio, M., Magagnoli, M., Bouabdallah, K., Heo, D. S., Diong, C. P., Munoz, J., Cao, A., Hiemeyer, F., Odongo, F., Garcia‐Vargas, J., Childs, B. H., Zinzani, P. L.

Source: Hematological oncology. 41:560-562

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185972204.0x000001&indx=1&recIds=ETOCvdc_100185972204.0x000001

MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VERSUS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA

Authors: Sehn, L., Sarkozy, C., Song, Y., Salar, A., Trotman, J., Zinzani, P. L., Zhang, J., Zhang, W., Fustier, P., Delarue, R., Nastoupil, L.

Source: Hematological oncology. 41:168-170

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185971959.0x000001&indx=1&recIds=ETOCvdc_100185971959.0x000001

Long‐term efficacy and safety of zanubrutinib (ZANU) in relapsed/refractory marginal zone lymphoma (R/R MZL): final analysis of the MAGNOLIA (BGB‐3111‐214) trial

Authors: Trotman, J., Tedeschi, A., Hu, B., Linton, K. M., McKay, P., Leitch, S., Jin, J., Sun, M., Sobieraj‐Teague, M., Zinzani, P. L., Browett, P., Thieblemont, C., Liberati, A. M., Bachy, E., Cavallo, F., Costello, R., Iyengar, S., Marasca, R., Mociková, H., Kim, J. S., Talaulikar, D., Liang, Z., Xu, J., Tankersley, C., Delarue, R., Co, M., Opat, S.

Source: Hematological oncology. 41:390-392

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185004701.0x000001&indx=1&recIds=ETOCvdc_100185004701.0x000001

An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatment

Authors: Lavie, D., Johnson, N., Borchmann, P., Herrera, A. F., Avigdor, A., Gasiorowski, R., Gregory, G., Keane, C., Vucinic, V., Bazargan, M., Herishanu, Y., Minuk, L., Tzoran, I., Andreadis, C., Armand, P., Kuruvilla, J., Zinzani, P. L., West, R. Marceau, Pillai, P., Marinello, P., Timmerman, J.

Source: Hematological oncology. 41:364-366

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185004499.0x000001&indx=1&recIds=ETOCvdc_100185004499.0x000001

Gut microbiome in DLBCL patients undergoing first‐line R‐CHOP regimen—The Oncopassport Study

Authors: Stefoni, V., Argnani, L., Casadei, B., Musuraca, G., Nanni, L., Pellegrini, C., Broccoli, A., Carella, M., Caldarulo, E., Mammoli, F., Conti, G., Turroni, S., Barone, M., Brigidi, P., Zinzani, P. L.

Source: Hematological oncology. 41:283-285

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185003849.0x000001&indx=1&recIds=ETOCvdc_100185003849.0x000001

FAVEZELIMAB PLUS PEMBROLIZUMAB IN ANTI–PD‐1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL): ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB

Authors: Armand, P., Zinzani, P. L., Timmerman, J., Johnson, N., Lavie, D., Thiagarajan, K., Topp, B., Pillai, P., Herrera, A. F.

Source: Hematological oncology. 41:163-165

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185002850.0x000001&indx=1&recIds=ETOCvdc_100185002850.0x000001

GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Authors: Hutchings, M., Avigdor, A., Sureda, A., Terol, M. J., Bosch, F., Corradini, P., Larsen, T. Stauffer, Domínguez, A. Rueda, Skarbnik, A., Jørgensen, J., Goldschmidt, N., Gurion, R., Zinzani, P. L., Pinto, A., Cordoba, R., Bottos, A., Huang, Z., Simko, S., Relf, J., Filézac de L'Etang, A., Sellam, G., Gritti, G.

Source: Hematological oncology. 41:138-140

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185009382.0x000001&indx=1&recIds=ETOCvdc_100185009382.0x000001

ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY

Authors: Zinzani, P. L., Mayer, J., Trotman, J., Bijou, F., Oliveira, A. C., Song, Y., Zhang, Q., Merli, M., Bouabdallah, K., Ganly, P. S., Zhang, H., Johnson, R., Garcia‐Sancho, A. M., Pulla, M. Provencio, Trněný, M., Yuen, S., Assouline, S. E., Auer, R., Ivanoa, E., Kim, P., Greenbaum, A., Huang, S., Delarue, R., Flowers, C. R.

Source: Hematological oncology. 41:119-121

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185009300.0x000001&indx=1&recIds=ETOCvdc_100185009300.0x000001

Exposure to obinutuzumab does not affect outcomes of SARS‐CoV‐2 infection in vaccinated patients with newly diagnosed advanced‐stage follicular lymphoma.

Authors: Pinto, A., Caltagirone, M., Battista, M., Gazzoli, G. C., Patti, C., Pennese, E., De Lorenzo, S., Pavone, V., Merli, M., Chiarenza, A., Gorgone, A. G., Piazza, F., Puccini, B., Noto, A., Arcaini, L., De Filippi, R., Zinzani, P. L., Ferreri, A. J. M., Ladetto, M., Ferrari, S.

Source: British Journal of Haematology; Dec2024, Vol. 205 Issue 6, p2219-2227, 9p

Subject Terms: SARS-CoV-2 Omicron variant, SARS-CoV-2 Delta variant, FOLLICULAR lymphoma, EMERGENCY management, DEATH rate

CART‐SIE REAL LIFE STUDY: PRIMARY MEDIASTINAL B‐CELL LYMPHOMA (PMBCL) HAVE A SUPERIOR OUTCOME COMPARED TO LARGE B‐CELL LYMPHOMA (LBCL) TREATED WITH AXICABTAGENE CILOLEUCEL

Authors: Chiappella, A., Dodero, A., Guidetti, A., Ljevar, S., Pennisi, M., Casadei, B., Galli, E., Di Rocco, A., Cutini, I., Barbui, A. M., Bramanti, S., Musso, M., Tisi, M. C., Carrabba, M. G, Martino, M., Farina, M., Botto, B., Grillo, G., Ladetto, M., Olivieri, J., Arcaini, L., Bermema, A., Miceli, R., Chiusolo, P., Zinzani, P. L., Corradini, P.

Source: Hematological oncology. 41:198-199

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185972387.0x000001&indx=1&recIds=ETOCvdc_100185972387.0x000001

Phase 1 trial of EO2463 peptide‐based immunotherapy as monotherapy and in combination with lenalidomide and rituximab in indolent non‐Hodgkin lymphoma; EONHL1‐20/SIDNEY

Authors: Pinto, A. A., Bosch, F., Bisneto, J. C. Villasboas, Sanz, R. García, Garcia, C. Grande, Smith, S. D., Wallace, D. S., Arcaini, L., Merryman, R., Marolleau, J., Filippi, R., Chêne, L., Bonny, C., Fagerberg, J., Friedberg, J. W., Ansel, S., Armand, P., Zinzani, P. L.

Source: Hematological oncology. 41:581-582

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185972189.0x000001&indx=1&recIds=ETOCvdc_100185972189.0x000001

BEGEV as salvage regimen in first setting for relapsed/refractory classical Hodgkin lymphoma

Authors: Carella, M., Argnani, L., Coppola, P. E., Nanni, L., Zoli, S., Cantelli, M., Morigi, A., Gentilini, M., Lolli, G., Bagnato, G., Sutto, E., Gugliotta, G., Casadei, B., Pellegrini, C., Stefoni, V., Broccoli, A., Zinzani, P. L.

Source: Hematological oncology. 41:360-361

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185004432.0x000001&indx=1&recIds=ETOCvdc_100185004432.0x000001

EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME

Authors: Frustaci, A. M., Montillo, M., Rossi, D., Zinzani, P. L., Motta, M., Gaidano, G., Quaresmini, G., Scarfò, L., Pietrasanta, D., Coscia, M., Deodato, M., Zamprogna, G., Cairoli, R., Stüssi, G., Zucca, E., Pileri, S., Zenz, T., Tedeschi, A.

Source: Hematological oncology. 41:62-63

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185004641.0x000001&indx=1&recIds=ETOCvdc_100185004641.0x000001

Role of autologous stem cell transplantation or salvage chemotherapy in relapsed/refractory classical Hodgkin lymphoma patients after immune checkpoint inhibitors

Authors: Pellegrini, C., Casadei, B., Sutto, E., Cantelli, M., Argnani, L., Broccoli, A., Gugliotta, G., Stefoni, V., Nanni, L., Carella, M., Zoli, S., Coppola, P. E., Lolli, G., Morigi, A., Bagnato, G., Gentilini, M., Zinzani, P. L.

Source: Hematological oncology. 41:368-369

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185004520.0x000001&indx=1&recIds=ETOCvdc_100185004520.0x000001

Interaction between gut microbiome and immune checkpoint inhibitor treatment in lymphoma patients: Final results of the MICRO‐LINF study

Authors: Casadei, B., Argnani, L., Guadagnuolo, S., Nanni, L., Pellegrini, C., Broccoli, A., Carella, M., Stefoni, V., Conti, G., Turroni, S., Barone, M., Brigidi, P., Zinzani, P. L.

Source: Hematological oncology. 41:310-311

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185004008.0x000001&indx=1&recIds=ETOCvdc_100185004008.0x000001

LACUTAMAB IN PATIENTS WITH ADVANCED MYCOSIS FUNGOIDES (MF): EFFICACY RESULTS ACCORDING TO UPDATED LYMPH NODE (LN) CLASSIFICATION IN THE TELLOMAK STUDY

Authors: Kim, Y. H., Bagot, M., Ortiz‐Romero, P. L., Zinzani, P. L., Beylot‐Barry, M., Dalle, S., Jacobsen, E., Combalia, A., Huen, A., Mehta‐Shah, N., Khodadoust, M. S., Mehta, A., Dereure, O., Battistella, M., Gru, A., Moins‐Teisserenc, H., Viotti, J., Paiva, C., Boyer‐Chammard, A., Porcu, P.

Source: Hematological oncology. 41:196-197

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185003076.0x000001&indx=1&recIds=ETOCvdc_100185003076.0x000001

AFM13 IN PATIENTS WITH CD30 POSITIVE RELAPSED OR REFRACTORY (R/R) PERIPHERAL T CELL LYMPHOMA (PTCL): RESULTS FROM THE PHASE 2 REDIRECT STUDY

Authors: Kim, W. S., Shortt, J., Zinzani, P. L., Mikhaylova, N., Marin‐Niebla, A., Radeski, D., Ribrag, V., Domenech, E. Domingo, Sawas, A., Alexis, K., Emig, M., Garcia, L., Overesch, A., Pietzko, K., Horwitz, S.

Source: Hematological oncology. 41:195-196

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185003088.0x000001&indx=1&recIds=ETOCvdc_100185003088.0x000001

PILOT PHASE II STUDY OF SELINEXOR IN COMBINATION WITH IFOSFAMIDE, ETOPOSIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMAS (R/R PTCLS)

Authors: Chiappella, A., Dodero, A., Carniti, C., Miceli, R., Bermema, A., Ladisa, V., Zinzani, P. L., Corradini, P.

Source: Hematological oncology. 41:845-846

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185009650.0x000001&indx=1&recIds=ETOCvdc_100185009650.0x000001

PHASE 1B OPEN‐LABEL STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA (LOTIS‐7)

Authors: Hess, B. T., Solh, M. M., Gandhi, M., Wang, Y., Qin, Y., Yu, E., Zinzani, P. L., Collins, G. P

Source: Hematological oncology. 41:824-825

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185009533.0x000001&indx=1&recIds=ETOCvdc_100185009533.0x000001